Biogen Company Profile (NASDAQ:BIIB)

About Biogen

Biogen logoBiogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BIIB
  • CUSIP: 09062X10
Key Metrics:
  • Previous Close: $299.66
  • 50 Day Moving Average: $304.26
  • 200 Day Moving Average: $282.10
  • 52-Week Range: $219,120,000.00 - $223.02
  • Trailing P/E Ratio: 16.98
  • Foreward P/E Ratio: 13.95
  • P/E Growth: 1.80
  • Market Cap: $63.69B
  • Outstanding Shares: 219,120,000
  • Beta: 0.95
  • Net Margins: 33.97%
  • Return on Equity: 40.59%
  • Return on Assets: 20.52%
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 2.96%
  • Quick Ratio: 2.56%
Additional Links:
Companies Related to Biogen:

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 10 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $343.05 (18.03% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
DateFirmActionRatingPrice TargetDetails
10/12/2016Leerink SwannSet Price TargetHold$367.00View Rating Details
10/12/2016HC WainwrightReiterated RatingBuy$360.00View Rating Details
10/7/2016JPMorgan Chase & Co.Reiterated RatingOverweight$386.00View Rating Details
10/5/2016Jefferies GroupLower Price TargetHold$323.00 -> $316.00View Rating Details
10/4/2016BMO Capital MarketsReiterated RatingMarket Perform$304.00View Rating Details
10/4/2016RBC Capital MarketsReiterated RatingBuy$375.00View Rating Details
9/22/2016Piper Jaffray Cos.Set Price TargetHold$333.00View Rating Details
9/22/2016Bank of America Corp.Reiterated RatingBuy$374.00View Rating Details
9/18/2016Credit Suisse Group AGSet Price TargetHold$322.00View Rating Details
9/16/2016Stifel NicolausReiterated RatingHoldView Rating Details
8/17/2016Morgan StanleyLower Price TargetOverweight$385.00 -> $368.00View Rating Details
8/10/2016Robert W. BairdReiterated RatingNeutral$284.00View Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
8/2/2016Raymond James Financial Inc.Boost Price TargetStrong-Buy$360.00 -> $375.00View Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$282.00View Rating Details
6/8/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/7/2016Citigroup Inc.DowngradeBuy -> Neutral$345.00 -> $295.00View Rating Details
5/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/23/2016Goldman Sachs Group Inc.Reiterated RatingHoldView Rating Details
1/27/2016William BlairReiterated RatingOutperformView Rating Details
1/22/2016Barclays PLCReiterated RatingBuy$420.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00View Rating Details
9/23/2015Oppenheimer Holdings Inc.Reiterated RatingSector PerformView Rating Details
8/11/2015Deutsche Bank AGReiterated RatingBuyView Rating Details
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details
12/3/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Biogen (NASDAQ:BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2016Q316$5.02$2.91 billionN/AView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.77$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.81$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biogen (NASDAQ:BIIB)
Current Year EPS Consensus Estimate: $20.07 EPS
Next Year EPS Consensus Estimate: $20.83 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$3.82$4.71$4.40
Q2 20164$4.41$4.74$4.62
Q3 20164$4.49$5.05$4.78
Q4 20164$4.81$5.12$4.97
Q1 20171$5.12$5.12$5.12
Q2 20171$5.19$5.19$5.19
Q3 20171$5.08$5.08$5.08
Q4 20172$4.94$5.06$5.00
(Data provided by Zacks Investment Research)


Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 86.21%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Biogen (NASDAQ:BIIB)
News IconBiogen Inc. (NASDAQ:BIIB) current consensus investment analysts ... - The Independent Republic (NASDAQ:BIIB) - October 22 at 8:07 AM
News IconEverence Capital Management Inc. Continues to Hold Position in Biogen Inc. (BIIB) - DailyQuint (NASDAQ:BIIB) - October 22 at 8:07 AM logoCan Biogen (BIIB) Keep the Earnings Streak Alive in Q3? - Yahoo Finance (NASDAQ:BIIB) - October 21 at 3:50 PM
News IconHot Biotech Stocks To Watch Right Now: Biogen Inc. (BIIB ... - The Independent Republic (NASDAQ:BIIB) - October 21 at 3:50 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit – BIIB (NASDAQ:BIIB) - October 21 at 3:50 PM
News IconBiogen Inc. (NASDAQ:BIIB) from Biotechnology – Todays Top Gains (NASDAQ:BIIB) - October 21 at 12:06 PM
News IconBiogen Inc. (NASDAQ:BIIB) – Top Stock from Healthcare Sector - The Daily Leicester (NASDAQ:BIIB) - October 20 at 8:42 PM
News IconFund Move to Note: Biogen INC (BIIB) Shareholder Paloma Partners Management Company Has Lowered Holding - Chester News (NASDAQ:BIIB) - October 20 at 8:42 PM
News IconShares of Biogen Inc. (BIIB) are sold by Henderson Group PLC (NASDAQ:BIIB) - October 20 at 9:44 AM logoCan Biogen (BIIB) Keep the Earnings Streak Alive in Q3? (NASDAQ:BIIB) - October 20 at 9:44 AM
News IconTrading the Biotech News: Exelixis, Inc. (NASDAQ:EXEL), Biogen Inc. (NASDAQ:BIIB) - The Voice Registrar (NASDAQ:BIIB) - October 19 at 4:41 PM
News Icon2 Sizzling Hot Biotechnology Stocks: Gilead Sciences Inc. (GILD), Biogen Inc. (BIIB) - The Independent Republic (NASDAQ:BIIB) - October 19 at 4:41 PM logoBiogen’s Multiple Sclerosis Drug Driving Its Growth This Year (NASDAQ:BIIB) - October 19 at 4:41 PM logoCommit To Buy Biogen At $180, Earn 5% Using Options (NASDAQ:BIIB) - October 19 at 8:44 AM
News IconUpdate on Biogen Inc. (NASDAQ:BIIB) for the day (NASDAQ:BIIB) - October 19 at 8:44 AM
News IconBiogen Inc. (NASDAQ:BIIB) missed earnings on 2 occasions - The Independent Republic (NASDAQ:BIIB) - October 18 at 3:48 PM
News IconTwo Biotechnology Names Are Hot: Kite Pharma, Inc. (KITE), Biogen Inc. (BIIB) - The Independent Republic (NASDAQ:BIIB) - October 18 at 3:48 PM
News IconHolder Move: Artal Group Sa Has Cut Its Biogen INC (Call) (BIIB ... - Chester News (NASDAQ:BIIB) - October 18 at 3:48 PM logoHow Did Markets React to the Fed’s September 2016 Minutes? (NASDAQ:BIIB) - October 18 at 3:48 PM logoBetter Buy: Biogen Inc. vs. Gilead Sciences, Inc. (NASDAQ:BIIB) - October 18 at 12:44 PM
News IconIntraday Active Biotech Stocks News: Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:BIIB) - October 18 at 8:40 AM
News IconNotable Mover: Biogen Idec Inc (NASDAQ:BIIB) Institutional Investors Sentiment - Post News (NASDAQ:BIIB) - October 18 at 8:40 AM logoCelgene Pitted Against Gilead, Biogen In Crohn's Drug Battle (NASDAQ:BIIB) - October 17 at 3:47 PM
News IconBiogen Inc. (BIIB) Stake Decreased by Algert Global LLC - Daily Quint - DailyQuint (NASDAQ:BIIB) - October 17 at 8:41 AM
News IconLeading stocks in today’s market: Biogen Inc. (NASDAQ:BIIB) (NASDAQ:BIIB) - October 16 at 3:46 PM
News IconBiogen Inc. (BIIB) Given a $367.00 Price Target by Leerink Swann Analysts (NASDAQ:BIIB) - October 16 at 3:46 PM
News IconBiotech stocks for your portfolio: Biogen Inc. (BIIB), Anavex Life Sciences Corp. (AVXL) - The Independent Republic (NASDAQ:BIIB) - October 14 at 3:46 PM
News IconTrading the Biotech News: Biogen Inc. (NASDAQ:BIIB), Amgen Inc ... - The Voice Registrar (NASDAQ:BIIB) - October 14 at 12:18 PM
News IconTime To Put On The Watch List? – Biogen Inc. (NASDAQ:BIIB ... - The Voice Registrar (NASDAQ:BIIB) - October 14 at 12:18 PM logoBiogen Stabilizes Near Major Support (NASDAQ:BIIB) - October 13 at 3:44 PM
News IconTwo Biotech Stocks Are Just So Hot Right Now: Biogen Inc. (BIIB), Celldex Therapeutics, Inc. (CLDX) - The Independent Republic (NASDAQ:BIIB) - October 13 at 11:32 AM logoBiogen Inc (BIIB) Reiterated as Market Perform, As Nusinersen Already in Stock: Analyst - TCC (NASDAQ:BIIB) - October 12 at 9:11 PM logoTherapy Focus - SMA Pipeline Contenders Await Nusinersen News - Seeking Alpha (NASDAQ:BIIB) - October 12 at 4:02 PM
News IconIn it for the Long Haul: Update on Biogen Inc. (NASDAQ:BIIB) - CSZ News (NASDAQ:BIIB) - October 12 at 4:02 PM logoBiogen Gets Competition for SMA Therapy (BIIB) - Investopedia (NASDAQ:BIIB) - October 12 at 4:02 PM
News IconSEC Exclusive: Biogen INC (BIIB) Stock Price Declined While Jackson Square Partners LLC Lifted Its Position by ... - Chester News (NASDAQ:BIIB) - October 12 at 4:02 PM
News IconHot Biotech Stocks To Watch Right Now: Biogen Inc. (BIIB), Agenus Inc. (AGEN) - The Independent Republic (NASDAQ:BIIB) - October 12 at 8:13 AM logoBiogen Gets Competition for SMA Therapy (BIIB) (NASDAQ:BIIB) - October 11 at 3:54 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention Biogen Inc (NASDAQ:BIIB), TransDigm Group Incorporated (NYSE:TDG) - The Voice Registrar (NASDAQ:BIIB) - October 10 at 3:45 PM logoHC Wainwright Weighs in on Biogen Inc (BIIB) Following World Muscle Society Congress - Smarter Analyst (NASDAQ:BIIB) - October 10 at 3:45 PM logoBetter Buy: Biogen vs. Celgene (NASDAQ:BIIB) - October 10 at 3:45 PM
News IconTwo Biotech Stocks Are Just So Hot Right Now: Biogen Inc. (BIIB), Pain Therapeutics Inc. (PTIE) - The Independent Republic (NASDAQ:BIIB) - October 10 at 8:35 AM logo3:27 am Biogen reports initial Phase 3 safety data in infantile-onset spinal muscular atrophy demonstrated favorable safety profile with no treatment related adverse events (NASDAQ:BIIB) - October 10 at 8:35 AM
News IconNew Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spin... (NASDAQ:BIIB) - October 8 at 3:46 PM
News IconSell-side Taking Aim at Shares of Biogen Idec Inc. (NASDAQ:BIIB) - CSZ News (NASDAQ:BIIB) - October 7 at 3:48 PM
News IconBiogen Inc. (NASDAQ:BIIB) added about 18.7 percent in value since last earnings - The Independent Republic (NASDAQ:BIIB) - October 6 at 3:48 PM
News IconTime To Put On The Watch List? - Biogen (NASDAQ:BIIB), Celgene (NASDAQ:CELG) - The Voice Registrar (NASDAQ:BIIB) - October 6 at 9:21 AM
News IconTop Gainers of the Day: Biogen Inc. (NASDAQ:BIIB) from Biotechnology (NASDAQ:BIIB) - October 5 at 4:04 PM
News IconFinancial Update of Biogen Inc. (NASDAQ:BIIB) - Newburgh Press (NASDAQ:BIIB) - October 5 at 8:45 AM
News Icon2 Stocks Analyst-Opinion Need Close Attention Biogen Inc (NASDAQ:BIIB), Energy Transfer Partners LP (NYSE:ETP) - The Voice Registrar (NASDAQ:BIIB) - October 4 at 3:47 PM


Biogen (NASDAQ:BIIB) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff